Table 1.

Demographic, clinical, and serological characteristics of patients with systemic sclerosis (SSc) and control subjects. Except where indicated otherwise, values are the number (%) of subjects. Disease duration was calculated since the first non-Raynaud’s symptom and did not differ significantly among subsets of patients with SSc.

CharacteristicsPatients with SSc, n = 250Controls, n = 263
Mean age, yrs ± SD55.9 ± 12.554.5 ± 12.7
  Male27 (10.8)46 (17.5)
  Female223 (89.2)217 (82.5)
Mean disease duration, yrs ± SD7.7 ± 6.9
Disease subset
  lcSSc146 (58.4)
  dcSSc104 (41.6)
Autoantibody positivity
  ANA227 (90.8)
  Anti-topo I77 (30.8)
  ACA91 (36.4)
Organ involvement
  ILD74 (29.6)
  PAH35 (14.0)
  • ACA: anticentromere antibodies; ANA: antinuclear antibodies; anti-topo I: antitopoisomerase I antibodies; dcSSc: diffuse cutaneous SSc; ILD: interstitial lung disease; lcSSc: limited cutaneous SSc; PAH: pulmonary arterial hypertension.